{"id":9061,"date":"2022-04-07T12:59:52","date_gmt":"2022-04-07T10:59:52","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=9061"},"modified":"2022-04-07T12:59:52","modified_gmt":"2022-04-07T10:59:52","slug":"andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/","title":{"rendered":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer"},"content":{"rendered":"<p>En vertu de cet accord, <strong>ReViral<\/strong>, soci\u00e9t\u00e9 priv\u00e9e biopharmaceutique en phase clinique qui se concentre sur la d\u00e9couverte, le d\u00e9veloppement et la commercialisation de nouvelles th\u00e9rapies antivirales, avec un accent initial sur le traitement du virus respiratoire syncytial (<strong>VRS<\/strong>), sera acquise pour un montant total pouvant atteindre 525 millions de dollars, y compris le paiement initial et les paiements li\u00e9s \u00e0 des \u00e9tapes de d\u00e9veloppement du portefeuille de produits. La transaction est sujette aux conditions habituelles de finalisation incluant des approbations r\u00e8glementaires.<\/p>\n<p>Andera a \u00e9t\u00e9 le co-chef de file dans le tour de financement de s\u00e9rie A de 21 millions de dollars en 2015 et a r\u00e9investi dans les tours de financement ult\u00e9rieurs aux c\u00f4t\u00e9s d&rsquo;un groupe d&rsquo;investisseurs internationaux de premier ordre.<\/p>\n<p>Le <strong>VRS<\/strong> est un agent pathog\u00e8ne respiratoire, qui peut entra\u00eener des infections des voies respiratoires inf\u00e9rieures (IVRI) graves et potentiellement mortelles chez les populations \u00e0 haut risque, notamment les jeunes nourrissons, les personnes immunod\u00e9prim\u00e9es et les personnes \u00e2g\u00e9es. On estime que le VRS est \u00e0 l&rsquo;origine d&rsquo;infections chez environ 64 millions de personnes, entra\u00eenant environ 160 000 d\u00e9c\u00e8s chaque ann\u00e9e dans le monde.<\/p>\n<p><strong>ReViral<\/strong> poss\u00e8de un portefeuille de candidats th\u00e9rapeutiques prometteurs, dont sisunatovir, un inhibiteur administr\u00e9 par voie orale con\u00e7u pour bloquer la fusion du virus VRS avec la cellule h\u00f4te. Sisunatovir est actuellement en phase 2 de d\u00e9veloppement clinique chez les nourrissons. Un deuxi\u00e8me programme se concentre sur l&rsquo;inhibition de la r\u00e9plication du VRS en ciblant la prot\u00e9ine N du virus. Le candidat principal de ce programme est actuellement en phase 1 de d\u00e9veloppement clinique.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Rapha\u00ebl Wisniewski<\/strong>, associ\u00e9 au sein d\u2019Andera Life Sciences et membre du conseil d&rsquo;administration de ReViral, commente : <em>\u00ab\u00a0Chez Andera Partners, nous sommes ravis d&rsquo;avoir soutenu une \u00e9quipe aussi talentueuse de d\u00e9veloppeurs de m\u00e9dicaments dans le domaine du VRS, pour lequel les options de traitement sont tr\u00e8s limit\u00e9es. Nous sommes extr\u00eamement fiers que le travail accompli \u00e0 ce jour ait \u00e9t\u00e9 reconnu par un leader de classe mondiale tel que Pfizer et le d\u00e9veloppement de ces importants produits th\u00e9rapeutiques sera poursuivi\u00a0\u00bb.<\/em><\/p>\n<p><em>\u00ab\u00a0Nous sommes reconnaissants \u00e0 Andera de nous avoir financ\u00e9s et soutenus depuis les premiers jours de la soci\u00e9t\u00e9, aux c\u00f4t\u00e9s d&rsquo;un groupe d&rsquo;investisseurs internationaux de premier plan. Andera a \u00e9t\u00e9 un partenaire exceptionnel avec lequel nous avons travaill\u00e9 pour passer d&rsquo;une soci\u00e9t\u00e9 de recherche en phase initiale \u00e0 une organisation en phase clinique\u00a0\u00bb<\/em>, a d\u00e9clar\u00e9 <strong>Alex C. Sapir<\/strong>, PDG de ReViral.<\/p>\n<p>Cette op\u00e9ration fait suite \u00e0 des transactions r\u00e9centes de M&amp;A dans les portefeuilles d\u2019Andera Life Sciences (vente de Sanifit \u00e0 Vifor, vente d\u2019Arvelle \u00e0 Angelini et vente de Corvidia \u00e0 Novo Nordisk) et s\u2019ajoute aux introductions en bourse d\u2019Axonics, Nyxoah et LogicBio.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En vertu de cet accord, ReViral, soci\u00e9t\u00e9 priv\u00e9e biopharmaceutique en phase clinique qui se concentre sur la d\u00e9couverte, le d\u00e9veloppement et la commercialisation de nouvelles th\u00e9rapies antivirales, avec un accent initial sur le traitement du virus respiratoire syncytial (VRS), sera acquise pour un montant total pouvant atteindre 525 millions de dollars, y compris le paiement&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-9061","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"En vertu de cet accord, ReViral, soci\u00e9t\u00e9 priv\u00e9e biopharmaceutique en phase clinique qui se concentre sur la d\u00e9couverte, le d\u00e9veloppement et la commercialisation de nouvelles th\u00e9rapies antivirales, avec un accent initial sur le traitement du virus respiratoire syncytial (VRS), sera acquise pour un montant total pouvant atteindre 525 millions de dollars, y compris le paiement...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-07T10:59:52+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer\",\"datePublished\":\"2022-04-07T10:59:52+00:00\",\"dateModified\":\"2022-04-07T10:59:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\"},\"wordCount\":506,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\",\"name\":\"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2022-04-07T10:59:52+00:00\",\"dateModified\":\"2022-04-07T10:59:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/","og_locale":"fr_FR","og_type":"article","og_title":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS","og_description":"En vertu de cet accord, ReViral, soci\u00e9t\u00e9 priv\u00e9e biopharmaceutique en phase clinique qui se concentre sur la d\u00e9couverte, le d\u00e9veloppement et la commercialisation de nouvelles th\u00e9rapies antivirales, avec un accent initial sur le traitement du virus respiratoire syncytial (VRS), sera acquise pour un montant total pouvant atteindre 525 millions de dollars, y compris le paiement...","og_url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2022-04-07T10:59:52+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer","datePublished":"2022-04-07T10:59:52+00:00","dateModified":"2022-04-07T10:59:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/"},"wordCount":506,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/","url":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/","name":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2022-04-07T10:59:52+00:00","dateModified":"2022-04-07T10:59:52+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/andera-partners-cede-reviral-societe-de-son-portefeuille-dedie-aux-sciences-de-la-vie-a-pfizer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Andera Partners c\u00e8de ReViral, soci\u00e9t\u00e9 de son portefeuille d\u00e9di\u00e9 aux sciences de la vie, \u00e0 Pfizer"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/9061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=9061"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/9061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=9061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=9061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}